Claims for Patent: 6,475,468

Summary for Patent: 6,475,468

Title:	Modulated release particles for aerosol delivery
Abstract:	A modulated release aerosol formulation is disclosed. The formulation comprises a polymer, e.g. Silica gel, fumed silica gel, having a selected medicament associated therewith, and a fluid carrier for carrying and delivering the construct.
Inventor(s):	Zhu; Yaping (Highland Park, NJ), Stefanos; Simon G. (Morris Plains, NJ), Kline; Lukeysha (Toms River, NJ), Adjei; Akwete L. (Bridgewater, NJ)
Assignee:	Aeropharm Technology Incorporated (N/A)
Application Number:	09/784,566
Patent Claims:	1. A modulated release aerosol formulation, which consists essentially of: a. a polymeric construct of a polysaccharide polymer selected from the group consisting of an alginic acid or a pharmaceutically acceptable salt thereof; guar gum; gum Karaya; gum Benjamin; plantago ovata gum; agar; carrageenan; gelatin; gumaribic; pectin; galaturonic acid or a mixture of any of the foregoing polymers, having a selected medicament associated therewith; and b. a fluid carrier for carrying and delivering said construct. 2. A modulated release aerosol formulation, which consists essentially of: a. a selected particulate medicament; b. particles of a polysaccharide polymer selected from the group of consisting of an alginic acid or a pharmaceutically acceptable salt thereof; guar gum; gum Karaya; gum Benjamin; plantago ovata gum; agar; carrageenan; gelatin; gumaribic; pectin; galaturonic acid or a mixture of any of the foregoing polymers, having said medicament associated therewith; and c. a fluid carrier for carrying and transporting said particles of polymer. 3. The formulation as defined in claim 1 wherein said medicament is a protein or peptide medicament having a molecular size ranging from about 1K Daltons. 4. The formulation as defined in claim 3 wherein said medicament is selected from the group consisting of an insulin, an insulin analog, an amylin, an immunodilating protein, an interleukin, an inteferon, an erythropoietan, a heparin, a thrombolytic, an antitrypsin, an antiprotease, a hormone, a growth factor, an enzyme, a nucleic acid, an immunoglobulin, an antibiotic, an antiinfective, a calcitonin, a hematopoietic factor, a vaccine, a vasoactive peptide, an antisense agent, an oligonucleotide, DNaze, a cyclosporin, ribavirin or a mixture of any of the foregoing medicaments. 5. The formulation as defined in claim 3 wherein said medicament is selected from the group consisting of an insulin, an insulin analog, an amylin, glucagon, LH-RH, deltirex, leuprolide, gosorelin, nafarelin, octreotide, somatostatin, a calcitonin, parathyroid hormone, TRH, growth hormone-releasing hormone, G-CSF, G-SF, a cytokine, rhDNAse, a heparin, an oligoneucleotide, ribavirin, glucagon, acetohexamide, chlorpropamide, tolazemide, tolbutamide, glipizide, glyburide, metformin, phentolamine, tumor neurosis factor (TNF), nerve growth factor (NGF), macrophage-colony stimulating factor (M-CSF), heparinase, bone morphogenic protein (BMP), hANP, glucagon-like peptide (GLP-1), renin, bradykinin, a bacitracin, a polymyxin, a colistin, tyrocidine, a gramicidin, a monoclonal antibody, a vaccine or a mixture of any of the foregoing medicaments. 6. The formulation of claim 2 wherein said polymer is present in an amount of about 0.000001 to about 10 percent by weight of the total weight of the formulation. 7. The formulation as defined in claim 1 wherein said fluid carrier is selected from the group of propellants consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3- heptafluoropropane or a mixture thereof. 8. The formulation as defined in claim 1 wherein said fluid carrier is a compressed gas selected from the group consisting of air, carbone dioxide, nitrogen and a mixture of any of the foregoing compressed gasses. 9. The formulation as defined in claim 1 wherein said fluid carrier is a hydrocarbon selected from the group consisting of n-butane, propane, isopentene and a mixture of any of the foregoing hydrocarbons. 10. A method of preparing a stable medicinal aerosol formulation according to claim 1, which comprises, (a) combining said selected medicament with said polymer to form said polymeric construct, wherein said medicament is associated with said polymer in an amount sufficient to provide a plurality of therapeutically effective doses; (b) combining said construct with a fluid carrier, where said carrier is present in an amount sufficient to transport and deliver a plurality of said therapeutically effective doses, to form a mixture; and (c) dispersing said mixture. 11. A formulation according to claim 1 in an aerosol canister equipped with a meter dose valve. 12. A metered dose inhaler containing a medicinal formulation, the formulation consisting essentially of: a. a particulate medicament in a therapeutically effective amount; b. a polysaccharide polymer selected from the group consisting of an alginic acid or a pharmaceutically acceptable salt thereof; guar gum; gum Karaya; gum Benjamin; plantago ovata gum; agar; carrageenan; gelatin; gumaribic; pectin; galacturonic acid or a mixture of any of the foregoing polymers with which said particulate medicament is associated to form a particulate polymeric construct; and c. a fluid carrier for containing and transporting said particulate polymeric construct. 13. A modulated release aerosol formulation, which comprises, a. a selected particulate medicament; b. particles of a polysaccharide polymer selected from the group consisting of an alginic acid or a pharmaceutically acceptable salt thereof; guar gum; gum Karaya; gum Benjamin; plantago ovata gum; agar; carrageenan; cellulose; gelatin; gumaribic; pectin; galaturonic acid or a mixture of any of the foregoing polymers having said medicament associated therewith; c. a fluid carrier for carrying and transporting said particles of polymer; and d. a stabilizer selected from the group consisting of (1) a first stabilizer selected from the group consisting of (a) an amino acid, (b) a derivative thereof and (c) a mixture of the foregoing; and (2) a second stabilizer of a water addition and (3) a mixture of (1) and (2).

Details for Patent 6,475,468

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Hoffmann-la Roche Inc.	PEGASYS COPEGUS COMBINATION PACK	peginterferon alfa-2a and ribavirin		125083	06/04/2004		2039-02-26
Schering Corporation A Subsidiary Of Merck & Co., Inc.	PEGINTRON/ REBETOL COMBO PACK	peginterferon alfa-2b and ribavirin		125196	06/13/2008		2039-02-26
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-02-26